Clinical Trials Logo

Clinical Trial Summary

This purpose of this study is to compare the pharmacokinetics (PK) of a single dose of MK-0616 in participants with moderate renal impairment (RI) to those of healthy matched control participants. This study is being conducted to assess the impact of moderate renal insufficiency on the PK of MK-0616.

Clinical Trial Description


Study Design

Related Conditions & MeSH terms

NCT number NCT05070390
Study type Interventional
Source Merck Sharp & Dohme Corp.
Status Not yet recruiting
Phase Phase 1
Start date October 25, 2021
Completion date May 24, 2022

See also
  Status Clinical Trial Phase
Completed NCT02128490 - Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout and Moderate Renal Impairment Phase 2
Completed NCT02742103 - A Study of CSL112 in Adults With Moderate Renal Impairment and Acute Myocardial Infarction Phase 2